Catalyst Event
InnoCare Pharma Ltd (9969) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
5/13/2026, 12:00:00 AM
Announced that the first subject has been dosed in the Phase 1 clinical trial of ICP-054 (ZB021), a novel oral IL-17AA/AF inhibitor for autoimmune diseases. Early-stage clinical progress is estimated to have a low market impact (>1%).
Korean Translation
자가면역질환 치료를 위한 신규 경구용 IL-17AA/AF 억제제인 ICP-054(ZB021)의 1상 임상시험에서 첫 번째 시험대상자 투여를 완료함. 초기 임상 단계 진전으로 인해 1% 이상의 시장 영향이 예상됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
D&D Pharmatech Inc (347850) · Other
The 48-week top-line results from the Phase 2 clinical trial of 'DD01', a MASH treatment, are scheduled to be presented at the European Association for the Study of the Liver (EASL) Congress 2026 (May 27-30) as a Late-Breaking Abstract; high impact is estimated due to the significant market potential for MASH treatments, which is expected.
5/27/2026, 12:00:00 AM